Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tc 99m Tilmanocept PK and Dosimetry in Rheumatoid Arthritis
NCT03241446Phase 1Withdrawn
- Sponsor
- Navidea Biopharmaceuticals, Inc.
- Start
- Sep 2017
- Primary completion
- Jan 2018
- Modality
- Radiopharmaceutical, Biologic
01
Overview
Phase 1, open-label trial of technetium tc 99m tilmanocept in rheumatoid arthritis (RA) (3 arms), sponsored by Navidea Biopharmaceuticals, Inc. Primary endpoints: Maximum Plasma Concentration at 1 day, Area Under the Curve at 2 days and 4 more. Planned start Sep 2017; status: withdrawn.
02
Drugs
technetium tc 99m tilmanocept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03241446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03241446.